MedTrace Logo

Huperzine A in Alzheimer's Disease

NCT00083590 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-02-21

No results posted yet for this study

Summary

The present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect on cognitive function.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Huperzine A

Sponsors & Collaborators

  • Alzheimer's Disease Cooperative Study (ADCS)

    collaborator OTHER

  • Neuro-Hitech

    collaborator INDUSTRY

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Paul S. Aisen, MD · Georgetown University Medical Center, Memory Disorders Program

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083590 on ClinicalTrials.gov